269 related articles for article (PubMed ID: 21856081)
41. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
[TBL] [Abstract][Full Text] [Related]
42. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
43. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view.
Costantino JP; Vogel VG
Clin Breast Cancer; 2001 Apr; 2(1):41-6. PubMed ID: 11899381
[TBL] [Abstract][Full Text] [Related]
44. Chemoprevention for high-risk women: tamoxifen and beyond.
Fabian CJ; Kimler BF
Breast J; 2001; 7(5):311-20. PubMed ID: 11906441
[TBL] [Abstract][Full Text] [Related]
45. Breast cancer chemoprevention.
Gabriel EM; Jatoi I
Expert Rev Anticancer Ther; 2012 Feb; 12(2):223-8. PubMed ID: 22316370
[TBL] [Abstract][Full Text] [Related]
46. Breast cancer prevention.
Euhus DM; Diaz J
Breast J; 2015; 21(1):76-81. PubMed ID: 25413630
[TBL] [Abstract][Full Text] [Related]
47. Molecular pathways: digoxin use and estrogen-sensitive cancers--risks and possible therapeutic implications.
Biggar RJ
Clin Cancer Res; 2012 Apr; 18(8):2133-7. PubMed ID: 22368159
[TBL] [Abstract][Full Text] [Related]
48. NICE recommends preventive drugs for breast cancer.
Wise J
BMJ; 2013 Jun; 346():f4116. PubMed ID: 23801701
[No Abstract] [Full Text] [Related]
49. Endocrine therapy for breast cancer prevention in high-risk women: clinical and economic considerations.
Groom AG; Younis T
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):245-55. PubMed ID: 26923683
[TBL] [Abstract][Full Text] [Related]
50. Breast cancer prevention trials.
Rhodes DJ; Hartmann LC; Perez EA
Curr Oncol Rep; 2000 Nov; 2(6):558-65. PubMed ID: 11122893
[TBL] [Abstract][Full Text] [Related]
51. Role of hormones in cancer prevention.
Vogel VG
Am Soc Clin Oncol Educ Book; 2014; ():34-40. PubMed ID: 24857058
[TBL] [Abstract][Full Text] [Related]
52. Primary prevention of breast cancer: new approaches.
Cummings SR
Maturitas; 2007 May; 57(1):39-41. PubMed ID: 17391879
[TBL] [Abstract][Full Text] [Related]
53. Chemoprevention of breast cancer.
Zelnak AB; O'Regan RM
Curr Probl Cancer; 2004; 28(4):201-17. PubMed ID: 15318323
[No Abstract] [Full Text] [Related]
54. [Chemoprevention for breast cancer].
Yamashiro H
Nihon Rinsho; 2012 Sep; 70 Suppl 7():88-91. PubMed ID: 23350371
[No Abstract] [Full Text] [Related]
55. Breast cancer chemoprevention.
Rosenbaum Smith SM; Osborne MP
Am J Surg; 2000 Oct; 180(4):249-51. PubMed ID: 11113429
[TBL] [Abstract][Full Text] [Related]
56. [Chemoprevention of Breast Cancer-Risk Reduction of Onset by Hormonal Agents].
Iizuka-Ohashi M; Taguchi T
Gan To Kagaku Ryoho; 2021 Dec; 48(12):1440-1446. PubMed ID: 34911907
[TBL] [Abstract][Full Text] [Related]
57. Chemoprevention of breast cancer in postmenopausal women.
Geller BA; Vogel VG
Breast Dis; 2005-2006; 24():79-92. PubMed ID: 16917141
[TBL] [Abstract][Full Text] [Related]
58. Breast Cancer Chemoprevention: A Practical Guide for the Primary Care Provider.
Farkas A; Vanderberg R; Merriam S; DiNardo D
J Womens Health (Larchmt); 2020 Jan; 29(1):46-56. PubMed ID: 31560601
[TBL] [Abstract][Full Text] [Related]
59. Endocrine therapy of breast cancer.
Lumachi F; Luisetto G; Basso SM; Basso U; Brunello A; Camozzi V
Curr Med Chem; 2011; 18(4):513-22. PubMed ID: 21143113
[TBL] [Abstract][Full Text] [Related]
60. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials.
Mocellin S; Pilati P; Briarava M; Nitti D
J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26582062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
